^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ALK positive

    i
    Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
    Entrez ID:
    238
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    1d
    ALK-Positive Lung Adenocarcinoma With Suspected Transformation to Squamous Cell Carcinoma in Lymph Node Metastases. (PubMed, Ann Thorac Surg Short Rep)
    The development of resistance to anaplastic lymphoma kinase (ALK) inhibitors appears to be inevitable in the treatment of non-small cell lung cancer because of several mechanisms. We report the case of resected lung adenocarcinoma with mediastinal lymph node metastasis that underwent histologic transformation to ALK-rearranged squamous cell carcinoma without prior exposure to ALK inhibition.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK rearrangement
    1d
    A structure-based virtual screening approach to identify novel anaplastic lymphoma kinase inhibitors. (PubMed, J Mol Model)
    Although FDA (Food and Drug Administration) approved inhibitors such as crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib have improved clinical outcomes, their efficacy is often challenged by resistance mechanisms, including secondary kinase domain mutations and activation of bypass pathways. Binding free energies and per-residue contributions were computed using MMGBSA. Boltz-2 machine learning platform to predict KD values and the top three hits were validated using PCA and free energy landscape.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    Xalkori (crizotinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • Alunbrig (brigatinib)
    1d
    Bringing Silicon to Drugs: Modular Construction of Sila-Pharmacophores for the Development of Target Protein Degraders. (PubMed, J Am Chem Soc)
    These findings underscore that silicon-centered drug motifs not only offer synthetic accessibility and convenience but also enhance drug-like properties. The silicon-carbon switch strategy introduced herein provides an innovative approach to new drug motif development, highlighting its extensive potential in drug discovery and opening new avenues for chemical biology research.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    1d
    Prognostic analysis and development of a prognostic model for EML4-ALK-positive lung cancer patients treated with ALK-TKIs. (PubMed, Front Med (Lausanne))
    The developed prognostic models show satisfactory prognostic performance and may assist in clinical decision-making and patient stratification. These findings warrant further validation in prospective, multicenter studies.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)
    |
    ALK positive
    1d
    The Eye Never Lies: When A Lesion Unveils Lung Cancer. (PubMed, Respirol Case Rep)
    Pembrolizumab was initiated; filamentous keratitis developed during therapy, and progression at three months prompted conventional chemotherapy. This case emphasizes the rarity of iris metastasis as the initial presentation of lung adenocarcinoma.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NKX2-1 (NK2 Homeobox 1) • NAPSA (Napsin A Aspartic Peptidase)
    |
    PD-L1 expression • ALK positive
    |
    Keytruda (pembrolizumab)
    1d
    SOHO State of the Art Updates and Next Questions | Peripheral T-Cell Lymphoma: Current Landscape and Emerging Questions. (PubMed, Clin Lymphoma Myeloma Leuk)
    Brentuximab vedotin-based regimens have reshaped frontline therapy for CD30-positive disease, while ongoing studies are exploring the role of novel therapies including epigenetic modulators, phosphatidylinositol 3-kinase (PI3K) and JAK inhibitors, and immune-based therapies across the PTCL spectrum. Future progress will depend on biomarker-driven clinical trials, refined patient selection, and the incorporation of genomic and immune signatures to personalize therapy.
    Review • Journal
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • TNFRSF8 positive
    |
    Adcetris (brentuximab vedotin)
    2d
    NRG-LU003: Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=10, Terminated, National Cancer Institute (NCI) | Trial completion date: Mar 2027 --> Mar 2026 | Active, not recruiting --> Terminated; Inadequate accrual rate
    Trial completion date • Trial termination
    |
    ALK positive • ALK rearrangement
    |
    cisplatin • Xalkori (crizotinib) • carboplatin • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Ensacove (ensartinib)
    2d
    Firmonertinib for Adjuvant Therapy in Completely Resected Stage IA EGFR-Mutated NSCLC (ChiCTR2600121611)
    P4, N=535, Recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital
    New P4 trial • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • RB1 (RB Transcriptional Corepressor 1) • FGFR (Fibroblast Growth Factor Receptor) • NRG1 (Neuregulin 1) • BRCA (Breast cancer early onset)
    |
    TP53 mutation • BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • HER-2 mutation • ALK positive • RET fusion • ALK fusion • FGFR mutation • RET mutation • ROS1 fusion • MET mutation • RB1 mutation • NRG1 fusion • KRAS G12 • BRCA mutation
    |
    Ivesa (firmonertinib)
    2d
    A Prospective, Multicenter Study of Perioperative MRD-Guided Adjuvant Immunotherapy in Patients With Stage II–III Non-Small Cell Lung Cancer (ChiCTR2600118144)
    P2, N=120, Recruiting, Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK mutation
    |
    carboplatin • paclitaxel • pemetrexed • AiRuiLi (adebrelimab)
    3d
    Mapping Real-world Rebiopsy Events to Treatment Trajectories in EGFR/ALK/ROS1-Driven Non-small-cell Lung Cancer: Insights from the AURORA Cohort. (PubMed, Clin Lung Cancer)
    This real-world analysis provides contemporary insight into rebiopsy practices and longitudinal treatment patterns in oncogene-driven NSCLC. By mapping biopsy events to treatment trajectories, this study highlights evolving real-world practice, with rebiopsy rates at progression increasing over time across EGFR, ALK, and ROS1 cohorts.
    Journal • Real-world evidence
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK positive • ROS1 positive
    4d
    Long-term outcomes and clinical features of stage III non-small-cell lung cancer harboring ALK rearrangements: a multicenter retrospective study of 176 patients. (PubMed, J Natl Cancer Cent)
    Stage III ALK-positive NSCLC is prone to relapse but local therapy combined with adjuvant ALK TKIs offers a promising strategy. Patients with EML4-ALK v1 mutations may show improved outcomes.
    Retrospective data • Journal
    |
    ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)
    |
    ALK positive • ALK rearrangement • ALK mutation • RET rearrangement
    4d
    Lung Cancer Driver Mutations in Middle Eastern Americans: Associations with Smoking and Comparative Analysis with Middle Eastern Populations. (PubMed, Avicenna J Med)
    Understanding these dynamics is essential for developing targeted public health strategies that address the unique challenges faced by this population, balancing their cultural heritage with the realities of modern American life. Further analysis and wider scope studies are necessary to explore the implications of these findings on health outcomes.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • ALK positive • ALK mutation • MET mutation
    |
    TruSight Oncology 500 Assay • TruSight Tumor 15 Assay